<DOC>
	<DOCNO>NCT00486213</DOCNO>
	<brief_summary>RATIONALE : Pyridoxine may help prevent hand-foot syndrome cause capecitabine patient cancer . It yet know whether pyridoxine effective placebo prevent hand-foot syndrome patient cancer . PURPOSE : This randomized phase III trial study pyridoxine see well work compare placebo prevent hand-foot syndrome cause capecitabine patient cancer .</brief_summary>
	<brief_title>Pyridoxine Preventing Hand-Foot Syndrome Caused Capecitabine Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare incidence capecitabine-induced palmar-plantar erythrodysesthesia ( hand-foot syndrome [ HFS ] ) ≥ grade 2 patient cancer treat pyridoxine hydrochloride v placebo . Secondary - Compare time onset HFS ≥ grade 2 patient treated regimen . - Compare quality life change patient treat regimen . - Identify factor predict toxicity capecitabine chemotherapy . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients stratify accord gender treatment setting ( adjuvant/neoadjuvant v palliative setting ) . Patients randomize 1 2 treatment arm . - Arm I : Beginning concurrently plan capecitabine treatment , patient receive oral pyridoxine hydrochloride daily day 1-21 . - Arm II : Beginning concurrently plan capecitabine treatment , patient receive oral placebo daily day 1-21 . In arm , treatment repeat every 21 day 8 course ( discontinuation capecitabine treatment ) . Quality life assess baseline , begin course 2 , 4 , 6 , 8 , end study .</detailed_description>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer Must receive singleagent capecitabine either adjuvant/neoadjuvant palliative setting dose ≥ 1000 mg/m² twice daily day 114 ( give 3week course ) PATIENT CHARACTERISTICS : Life expectancy &gt; 12 week No preexist neuropathy No known allergy pyridoxine hydrochloride incipients No dermatologic condition , opinion physician , may affect hand foot may complicate evaluation study treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior capecitabine Concurrent radiotherapy , steroid , and/or biological therapy ( e.g. , trastuzumab [ Herceptin® ] bevacizumab ) allow provide cause handfoot syndrome ( HFS ) No concurrent drug ( e.g. , docetaxel doxorubicin hydrochloride liposome ) cause HFS No concurrent drug ( e.g. , oxaliplatin taxanes ) cause neuropathy No concurrent pyridoxine hydrochloridecontaining preparation ( e.g. , multivitamins vitamin B complex ) No concurrent overthecounter product contain urea lactic acid No concurrent drug report drug interaction pyridoxine hydrochloride ( e.g. , cycloserine ; hydralazine ; immunosuppressant ; isoniazid ; levodopa ; estrogen estrogencontaining contraceptive ; penicillamine ; phenobarbitone ; phenytoin ; pyrazinamide )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>dermatologic complication</keyword>
	<keyword>chemotherapeutic agent toxicity</keyword>
	<keyword>palmar-plantar erythrodysesthesia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>